$92.6 Million is the total value of Corriente Advisors, LLC's 11 reported holdings in Q1 2020. The portfolio turnover from Q4 2019 to Q1 2020 was 80.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| RETA | Sell | REATA PHARMACEUTICALS INCcl a | $27,425,000 | -30.1% | 190,000 | -1.0% | 29.60% | +40.4% |
| MAXR | Sell | MAXAR TECHNOLOGIES INC | $18,040,000 | -57.1% | 1,689,100 | -37.0% | 19.47% | -13.8% |
| BLU | Sell | BELLUS HEALTH INC NEW | $1,484,000 | -11.2% | 148,666 | -32.4% | 1.60% | +78.4% |
| GFI | Exit | GOLD FIELDS LTD NEWsponsored adr | $0 | – | -250,000 | -100.0% | -0.89% | – |
| RCKT | Exit | ROCKET PHARMACEUTICALS INC | $0 | – | -88,927 | -100.0% | -1.09% | – |
| DIS | Exit | DISNEY WALT CO | $0 | – | -15,000 | -100.0% | -1.16% | – |
| EQX | Exit | EQUINOX GOLD CORP | $0 | – | -300,000 | -100.0% | -1.24% | – |
| SPCEWS | Exit | VIRGIN GALCTC HLDNG CL A EQY WARRANTcall | $0 | – | -252,983 | -100.0% | -1.57% | – |
| EIGR | Exit | EIGER BIOPHARMACEUTICALS INC | $0 | – | -203,898 | -100.0% | -1.63% | – |
| GBT | Exit | GLOBAL BLOOD THERAPEUTICS IN | $0 | – | -40,000 | -100.0% | -1.71% | – |
| Exit | CATABASIS PHARMACEUTICALS IN | $0 | – | -617,084 | -100.0% | -1.96% | – | |
| INTEQ | Exit | INTELSAT S A | $0 | – | -1,631,227 | -100.0% | -6.16% | – |
| TPTX | Exit | TURNING POINT THERAPEUTICS I | $0 | – | -285,000 | -100.0% | -9.54% | – |
| QURE | Exit | UNIQURE NV | $0 | – | -252,500 | -100.0% | -9.72% | – |
| SPCE | Exit | VIRGIN GALACTIC HOLDINGS CL A ORD | $0 | – | -2,411,729 | -100.0% | -14.96% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-05-18
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CUE BIOPHARMA INC | 8 | Q3 2021 | 26.7% |
| MAXAR TECHNOLOGIES INC | 7 | Q2 2021 | 41.3% |
| REATA PHARMACEUTICALS INC | 6 | Q2 2021 | 29.6% |
| REPLIMUNE GROUP INC | 5 | Q2 2021 | 12.1% |
| APTOSE BIOSCIENCES INC | 5 | Q4 2020 | 18.7% |
| CARDIFF ONCOLOGY INC | 5 | Q2 2021 | 9.5% |
| DIAMEDICA THERAPEUTICS INC | 5 | Q2 2021 | 2.9% |
| TFF PHARMACEUTICALS INC | 4 | Q3 2021 | 15.2% |
| INVESCO QQQ TR | 3 | Q3 2022 | 94.7% |
| LANTERN PHARMA INC | 3 | Q3 2021 | 13.5% |
View Corriente Advisors, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Cardiff Oncology, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| Cue Biopharma, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| TFF Pharmaceuticals, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| CATABASIS PHARMACEUTICALS INCSold out | February 16, 2021 | 0 | 0.0% |
| NAUTILUS, INC.Sold out | February 16, 2021 | 0 | 0.0% |
| Maxar Technologies Inc. | November 26, 2019 | 2,920,750 | 4.9% |
| CATABASIS PHARMACEUTICALS INC | February 23, 2018 | 1,692,899 | 7.3% |
| NEUROLOGIX INC/DE | February 14, 2011 | 16,858,224 | 37.7% |
| AMERICAN VANTAGE COMPANIESSold out | February 16, 2010 | 0 | 0.0% |
| AspenBio Pharma, Inc.Sold out | February 16, 2010 | 0 | 0.0% |
View Corriente Advisors, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-09 |
| 13F-HR | 2023-05-10 |
| 13F-HR | 2023-02-15 |
| 13F-HR | 2022-11-15 |
| 13F-HR | 2022-08-16 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-15 |
| SC 13G/A | 2022-02-14 |
View Corriente Advisors, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.